Abstract:BackgroundEpithelial-to-mesenchymal transition (EMT) is a key step of the progression of tumor cell metastasis. Recent work has demonstrated some miRNAs play critical roles in EMT. In this study, we focused on the roles of miR-300 in regulating EMT.MethodsThe expression levels of miR-300 were examined in epithelial carcinoma cells that underwent an EMT using quantitative reverse transcription-PCR. The role of miR-300 in EMT was investigated by transfection of the miR-300 mimic or inhibitor in natural epithelial-mesenchymal phenotype cell line pairs and in transforming growth factor (TGF) beta-induced EMT cell models. A luciferase reporter assay and a rescue experiment were conducted to confirm the target gene of miR-300. The efficacy of miR-300 against tumor invasion and metastasis was evaluated both in vitro and in vivo. Correlation analysis between miR-300 expression and the expression levels of its target gene, as well as tumor metastasis was performed in specimens from patients with head and neck squamous cell carcinoma (HNSCC).ResultsMiR-300 was found down-regulated in the HNSCC cells and breast cancer cells that underwent EMT. Ectopic expression of miR-300 effectively blocked TGF-beta-induced EMT and reversed the phenotype of EMT in HN-12 and MDA-MB-231 cells, but inhibition of miR-300 in the epithelial phenotype cells, HN-4 and MCF-7 cells, could induce EMT. The luciferase reporter assay and the rescue assay results showed that miR-300 directly targets the 3′UTR of Twist. Enforced miR-300 expression suppressed cell invasion in vitro and experimental metastasis in vivo. Clinically, miR-300 expression was found inversely correlated with Twist expression and reduced miR-300 was associated with metastasis in patient specimens.ConclusionsDown-regulation of miR-300 is required for EMT initiation and maintenance. MiR-300 may negatively regulate EMT by direct targeting Twist and therefore inhibit cancer cell invasion and metastasis, which implicates miR-300 as an attractive candidate for cancer therapy.

Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression

AKT-ions with a TWIST between EMT and MET.

MiR-526b Suppresses Cell Proliferation, Cell Invasion and Epithelial-Mesenchymal Transition in Breast Cancer by Targeting Twist1

The Role of TWIST1 in Epithelial-Mesenchymal Transition and Cancers

Twist Regulation of EMT and Its Clinical Significance in Monitoring Circulating Tumor Cells and Evaluating Effects of Anticancer Drugs

ZNF451 Stabilizes TWIST2 Through SUMOylation and Promotes Epithelial-Mesenchymal Transition.

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer

Twist Mediates an Aggressive Phenotype in Human Colorectal Cancer Cells.

Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms

Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein

miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis

Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.

Stem-cell-like Properties and Epithelial Plasticity Arise As Stable Traits after Transient Twist1 Activation.

TWIST1 Plays Role in Expression of Stemness State Markers in ESCC

Mir-214-3p Inhibits Epithelial-to-mesenchymal Transition and Metastasis of Endometrial Cancer Cells by Targeting TWIST1

TWIST1 and BMI1 in Cancer Metastasis and Chemoresistance

Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions

TWIST1 Drives Cytotoxic CD8+ T-Cell Exhaustion through Transcriptional Activation of CD274 (PD-L1) Expression in Breast Cancer Cells

Twist1-mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells.

Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells

Negative regulation of TIMP1 is mediated by transcription factor TWIST1